 Twist Bioscience Corporation NASDAQ: TWST reported a 65 YY increase in its third-quarter revenues to 35 million, beating the Wall Street estimate of 32.27 million, driven by strength in next-generation sequencing revenues. In the Q3 conference call, Twist said that next-generation sequencing NGS revenues were 18.7 million, up twofold from 9.1 million a year ago, driven by an expanding pipeline and an increase in the number of applications, including liquid biopsy. 